Squamous cell carcinoma of the skin: Difference between revisions
(Created page with "<section begin="dermatology" /> * Second most common skin cancer * Risk factors ** Chronic sun exposure ** Precancerous lesions *** Actinic keratosis *** Bowen disease (SCC in situ) *** Leukoplakia ** Radiation ** Chronic scars, ulcers ** Arsenic, tar * Clinical features ** Painless, non-healing, bleeding ulcer or nodule ** Rapid growing ** On sun-exposed areas *** Face and neck *** Lower lip * Prognosis ** 5% risk of metastasis * Diagnosis ** Punch biopsy * Treatment **...") |
m (Nikolas moved page Squamous cell carcinoma to Squamous cell carcinoma of the skin without leaving a redirect) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
<section begin="dermatology" /> | <section begin="dermatology" /><section begin="oncology" /> | ||
* Second most common skin cancer | * Epidemiology | ||
** SCC accounts for 18% of all skin cancer | |||
** Second most common skin cancer, after BCC | |||
* Risk factors | * Risk factors | ||
** Chronic sun exposure | ** Chronic sun exposure | ||
** Transplantation (transplant-related immunosuppression increases the risk 65-fold) | |||
** Precancerous lesions | ** Precancerous lesions | ||
*** Actinic keratosis | *** Actinic keratosis | ||
| Line 17: | Line 20: | ||
*** Lower lip | *** Lower lip | ||
* Prognosis | * Prognosis | ||
** | ** Low risk of metastasis (5%) | ||
** Worse prognosis in transplant patients | |||
* Diagnosis | * Diagnosis | ||
** Punch biopsy | ** Punch biopsy or after surgical excision | ||
* Treatment | * Treatment | ||
** Surgical excision with 5 mm safety border | ** Surgery | ||
** | *** Surgical excision with 5 mm safety border | ||
*** Primary treatment is almost all cases | |||
** Radiotherapy | |||
*** If surgery is not an option | |||
*** As adjuvant therapy if high-risk features are discovered during pathological staging | |||
** Immune therapy | |||
*** For advanced SCC | |||
*** Cemiplimab – anti-PD-1 | |||
** Alternatives for superficial and small SCCs | |||
*** Cryosurgery | |||
** Mohs micrographic surgery | ** Mohs micrographic surgery | ||
** For low-risk, small | ** For low-risk, small SCC | ||
*** Cryotherapy | *** Cryotherapy | ||
*** Curettage | *** Curettage | ||
| Line 39: | Line 52: | ||
** Abdominal US | ** Abdominal US | ||
** Sun protection | ** Sun protection | ||
<section end="dermatology" /> | <section end="dermatology" /><section end="oncology" /> | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
Latest revision as of 14:03, 11 October 2024
- Epidemiology
- SCC accounts for 18% of all skin cancer
- Second most common skin cancer, after BCC
- Risk factors
- Chronic sun exposure
- Transplantation (transplant-related immunosuppression increases the risk 65-fold)
- Precancerous lesions
- Actinic keratosis
- Bowen disease (SCC in situ)
- Leukoplakia
- Radiation
- Chronic scars, ulcers
- Arsenic, tar
- Clinical features
- Painless, non-healing, bleeding ulcer or nodule
- Rapid growing
- On sun-exposed areas
- Face and neck
- Lower lip
- Prognosis
- Low risk of metastasis (5%)
- Worse prognosis in transplant patients
- Diagnosis
- Punch biopsy or after surgical excision
- Treatment
- Surgery
- Surgical excision with 5 mm safety border
- Primary treatment is almost all cases
- Radiotherapy
- If surgery is not an option
- As adjuvant therapy if high-risk features are discovered during pathological staging
- Immune therapy
- For advanced SCC
- Cemiplimab – anti-PD-1
- Alternatives for superficial and small SCCs
- Cryosurgery
- Mohs micrographic surgery
- For low-risk, small SCC
- Cryotherapy
- Curettage
- For metastasis
- Chemotherapy
- Platina
- 5-FU
- EGFR inhibitors – cetuximab
- PD-1 inhibitor – cemeplimab
- Chemotherapy
- Surgery
- Follow-up
- Physical examination
- Regional ultrasound
- Chest x-ray
- Abdominal US
- Sun protection